DK2660593T3 - Bestemmelse af niveauer af immunogene glutenpeptider i humane prøver - Google Patents
Bestemmelse af niveauer af immunogene glutenpeptider i humane prøver Download PDFInfo
- Publication number
- DK2660593T3 DK2660593T3 DK11852781.1T DK11852781T DK2660593T3 DK 2660593 T3 DK2660593 T3 DK 2660593T3 DK 11852781 T DK11852781 T DK 11852781T DK 2660593 T3 DK2660593 T3 DK 2660593T3
- Authority
- DK
- Denmark
- Prior art keywords
- gluten
- seq
- peptides
- monitoring
- gliadin
- Prior art date
Links
- 108010068370 Glutens Proteins 0.000 title claims description 124
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 117
- 235000021312 gluten Nutrition 0.000 title claims description 113
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 84
- 230000002163 immunogen Effects 0.000 title claims description 10
- 238000000034 method Methods 0.000 claims description 57
- 108010061711 Gliadin Proteins 0.000 claims description 49
- 235000006171 gluten free diet Nutrition 0.000 claims description 38
- 235000020884 gluten-free diet Nutrition 0.000 claims description 38
- 238000001514 detection method Methods 0.000 claims description 25
- 238000002965 ELISA Methods 0.000 claims description 22
- 238000012544 monitoring process Methods 0.000 claims description 21
- 208000015943 Coeliac disease Diseases 0.000 claims description 15
- 230000002860 competitive effect Effects 0.000 claims description 14
- 230000001900 immune effect Effects 0.000 claims description 13
- 108090000284 Pepsin A Proteins 0.000 claims description 11
- 102000057297 Pepsin A Human genes 0.000 claims description 11
- 108090000631 Trypsin Proteins 0.000 claims description 11
- 102000004142 Trypsin Human genes 0.000 claims description 11
- 231100000110 immunotoxic Toxicity 0.000 claims description 11
- 230000002625 immunotoxic effect Effects 0.000 claims description 11
- 229940111202 pepsin Drugs 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 229940088598 enzyme Drugs 0.000 claims description 10
- 239000012588 trypsin Substances 0.000 claims description 10
- 238000001262 western blot Methods 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 6
- 238000003118 sandwich ELISA Methods 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 3
- 238000012207 quantitative assay Methods 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 238000012206 semi-quantitative assay Methods 0.000 claims 1
- 230000029087 digestion Effects 0.000 description 43
- 210000003608 fece Anatomy 0.000 description 36
- 230000002496 gastric effect Effects 0.000 description 36
- 235000005911 diet Nutrition 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 230000037213 diet Effects 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 16
- 230000000968 intestinal effect Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 231100000331 toxic Toxicity 0.000 description 11
- 230000002588 toxic effect Effects 0.000 description 11
- 235000013305 food Nutrition 0.000 description 10
- 230000002550 fecal effect Effects 0.000 description 9
- 108090000317 Chymotrypsin Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 229960002376 chymotrypsin Drugs 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 108060006613 prolamin Proteins 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- XXRYFVCIMARHRS-UHFFFAOYSA-N propan-2-yl n-dimethoxyphosphorylcarbamate Chemical compound COP(=O)(OC)NC(=O)OC(C)C XXRYFVCIMARHRS-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 235000013339 cereals Nutrition 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- UCXQIIIFOOGYEM-ULQDDVLXSA-N Leu-Pro-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCXQIIIFOOGYEM-ULQDDVLXSA-N 0.000 description 5
- 208000021329 Refractory celiac disease Diseases 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 230000017854 proteolysis Effects 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 4
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 235000020790 strict gluten-free diet Nutrition 0.000 description 4
- 108010020532 tyrosyl-proline Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- ZVEQWRWMRFIVSD-HRCADAONSA-N Pro-Phe-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N3CCC[C@@H]3C(=O)O ZVEQWRWMRFIVSD-HRCADAONSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000010324 immunological assay Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- HZWWPUTXBJEENE-UHFFFAOYSA-N 5-amino-2-[[1-[5-amino-2-[[1-[2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CCC(C(=O)NC(CCC(N)=O)C(=O)N2C(CCC2)C(=O)NC(CCC(N)=O)C(O)=O)N1C(=O)C(N)CC1=CC=C(O)C=C1 HZWWPUTXBJEENE-UHFFFAOYSA-N 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 2
- XXXXOVFBXRERQL-ULQDDVLXSA-N Leu-Pro-Phe Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XXXXOVFBXRERQL-ULQDDVLXSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 231100000386 immunotoxicity Toxicity 0.000 description 2
- 230000007688 immunotoxicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LOFGQZYYARWABM-BYPYZUCNSA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoyl chloride Chemical compound ClC(=O)[C@@H](N)CCCNC(N)=N LOFGQZYYARWABM-BYPYZUCNSA-N 0.000 description 1
- 101800000535 3C-like proteinase Proteins 0.000 description 1
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 238000001135 Friedman test Methods 0.000 description 1
- 101710087459 Gamma-gliadin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- KWLWZYMNUZJKMZ-IHRRRGAJSA-N Leu-Pro-Leu Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O KWLWZYMNUZJKMZ-IHRRRGAJSA-N 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000219823 Medicago Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 1
- 101710183587 Omega-gliadin Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000288047 Phasianus colchicus Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- CPRLKHJUFAXVTD-ULQDDVLXSA-N Pro-Leu-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CPRLKHJUFAXVTD-ULQDDVLXSA-N 0.000 description 1
- IALSFJSONJZBKB-HRCADAONSA-N Pro-Tyr-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@@H]3C(=O)O IALSFJSONJZBKB-HRCADAONSA-N 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001479493 Sousa Species 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 238000003487 electrochemical reaction Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000021071 low fiber diet Nutrition 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/02—Food
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (10)
1. Fremgangsmåde til overvågning af indtaget gluten ved detektering af immunotoksiske peptider i fæces, kendetegnet ved anvendelsen af immunologiske fremgangsmåder, hvor der anvendes antistoffer, der er specifikt reaktive over for epitoper fra gliadin 33-mer-peptidet ifølge SEQ ID NO: 1 udvalgt fra SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8.
2. Fremgangsmåde til overvågning af indtaget gluten ifølge krav 1, hvor der i de immunologiske fremgangsmåder anvendes mindst ét af de monoklonale antistoffer G12, A1 og R5.
3. Fremgangsmåde til overvågning af indtaget gluten ifølge krav 1 eller 2, hvor de immunologiske fremgangsmåder er et indirekte ELISA, et kompetitivt ELISA, et sandwich-ELISA, immunokromatografiske teststrimler, fluorescerende immunomikropartikler, magnetiske immunopartikler, Western blot, elektroniske biosensorer eller resonansbiosensorer.
4. Fremgangsmåde til overvågning af indtaget gluten ifølge et hvilket som helst af kravene 1 til 3, hvor der i de immunologiske fremgangsmåder anvendes det monoklonale antistof G12 konjugeret til et enzym, der muliggør et kvantitativt assay ved anvendelse af kromogene, fluorogene eller luminescerende substrater.
5. Fremgangsmåde til overvågning af indtaget gluten ifølge et hvilket som helst af kravene 1 til 4, kendetegnet ved anvendelse som en referencestandard af nogle af peptiderne fra krav 1.
6. Fremgangsmåde til overvågning af indtaget gluten ifølge et hvilket som helst af kravene 1 til 4, kendetegnet ved, at gliadin hydrolyseret ved hjælp af pepsin og trypsin anvendes som referencestandard.
7. Fremgangsmåde til overvågning af indtaget gluten ifølge krav 1 eller 2, hvor der i de immunologiske fremgangsmåder anvendes mindst ét af de monoklonale anti-gliadin-antistoffer, G12 og A1, til udførelse af et semikvantitativt assay baseret på immunokromatografiske teststrimler til hurtig detektering.
8. Anvendelse af analytiske fremgangsmåder ifølge et hvilket som helst af kravene 1 til 7 til overvågning af overholdelse af glutenfri kost.
9. Anvendelse af analytiske fremgangsmåder ifølge et hvilket som helst af kravene 1 til 7 til detektering af ukontrolleret glutenindtagelse hos cøliakipatienter efter en glutenfri kost, men med refraktære og akutte symptomer på cøliaki.
10. Anvendelse af analytiske fremgangsmåder ifølge et hvilket som helst af kravene 1 til 7 til overvågning af virkningsgraden for terapier relateret til elimineringen af immunogene glutenpeptider.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201001633A ES2385455B2 (es) | 2010-12-28 | 2010-12-28 | Determinación de niveles de péptidos inmunogénicos del gluten en muestras humanas. |
| PCT/ES2011/000379 WO2012089868A2 (es) | 2010-12-28 | 2011-12-28 | Determinación de niveles de péptidos inmunogénicos del gluten en muestras humanas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2660593T3 true DK2660593T3 (da) | 2019-02-18 |
Family
ID=46383573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11852781.1T DK2660593T3 (da) | 2010-12-28 | 2011-12-28 | Bestemmelse af niveauer af immunogene glutenpeptider i humane prøver |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9410962B2 (da) |
| EP (1) | EP2660593B1 (da) |
| CA (1) | CA2823440C (da) |
| DK (1) | DK2660593T3 (da) |
| ES (2) | ES2385455B2 (da) |
| PL (1) | PL2660593T3 (da) |
| PT (1) | PT2660593T (da) |
| WO (1) | WO2012089868A2 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10466238B2 (en) * | 2010-12-28 | 2019-11-05 | Universidad De Sevilla | Determination of levels of immunogenic gluten peptides in human samples |
| WO2013098441A1 (es) * | 2011-12-29 | 2013-07-04 | Universidad De Sevilla | Determinación de niveles de péptidos inmunogénicos del gluten en muestras humanas |
| ES2556177B1 (es) * | 2014-07-09 | 2016-10-20 | Universidad De Sevilla | Detección de péptidos del gluten en fluidos humanos |
| US9738920B2 (en) * | 2015-01-16 | 2017-08-22 | General Mills, Inc. | In vitro method for estimating in vivo protein digestibility |
| BR102021012841A2 (pt) * | 2021-06-28 | 2023-01-03 | Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein | Sistema para acompanhamento de consumo de glúten e predição de associação de indisposição a consumo de glúten |
| ES2982932B2 (es) * | 2023-03-16 | 2025-04-11 | Biomedal SL | Procedimiento para la determinacion del estado de permeabilidad intestinal |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) * | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| US7462688B2 (en) * | 2002-05-14 | 2008-12-09 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for diagnostic and therapeutic methods for celiac sprue |
| ES2214108B1 (es) * | 2002-08-16 | 2005-11-16 | Consejo Sup. Investig. Cientificas | Sistema y procedimiento inmunocromatografico para la identificacion simultanea de anticuerpos frente a aga y t-tg, y su uso en el diagnostico de enfermedad celiaca. |
| ATE554392T1 (de) * | 2002-11-20 | 2012-05-15 | Univ Leland Stanford Junior | Diagnoseverfahren für sprue/zöliakie |
| US7563864B2 (en) * | 2004-04-26 | 2009-07-21 | Celiac Sprue Research Foundation | Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten |
| US7892763B2 (en) * | 2009-01-26 | 2011-02-22 | Dodds W Jean | Multi-stage nutrigenomic diagnostic food sensitivity testing in animals |
-
2010
- 2010-12-28 ES ES201001633A patent/ES2385455B2/es active Active
-
2011
- 2011-12-28 WO PCT/ES2011/000379 patent/WO2012089868A2/es not_active Ceased
- 2011-12-28 EP EP11852781.1A patent/EP2660593B1/en active Active
- 2011-12-28 PL PL11852781T patent/PL2660593T3/pl unknown
- 2011-12-28 US US13/977,247 patent/US9410962B2/en active Active
- 2011-12-28 ES ES11852781T patent/ES2715181T3/es active Active
- 2011-12-28 DK DK11852781.1T patent/DK2660593T3/da active
- 2011-12-28 PT PT11852781T patent/PT2660593T/pt unknown
- 2011-12-28 CA CA2823440A patent/CA2823440C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2385455B2 (es) | 2013-09-25 |
| WO2012089868A2 (es) | 2012-07-05 |
| US9410962B2 (en) | 2016-08-09 |
| CA2823440C (en) | 2020-02-18 |
| CA2823440A1 (en) | 2012-07-05 |
| ES2385455A1 (es) | 2012-07-25 |
| EP2660593A4 (en) | 2014-10-08 |
| ES2715181T3 (es) | 2019-06-03 |
| US20140178903A1 (en) | 2014-06-26 |
| EP2660593A2 (en) | 2013-11-06 |
| PT2660593T (pt) | 2019-02-06 |
| EP2660593B1 (en) | 2018-10-31 |
| WO2012089868A3 (es) | 2012-10-11 |
| PL2660593T3 (pl) | 2019-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Comino et al. | Monitoring of gluten-free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces | |
| Koehler et al. | Celiac disease and gluten: multidisciplinary challenges and opportunities | |
| DK2660593T3 (da) | Bestemmelse af niveauer af immunogene glutenpeptider i humane prøver | |
| Wieser et al. | The biochemical basis of celiac disease | |
| RU2635516C2 (ru) | Способы и устройство для обнаружения глютеновой чувствительности и ее дифференцирования с целиакией | |
| Elli et al. | Immunological effects of transglutaminase-treated gluten in coeliac disease | |
| Ballabio et al. | Molecular characterisation of 36 oat varieties and in vitro assessment of their suitability for coeliacs’ diet | |
| Courtois et al. | Detection of wheat allergens using 2D Western blot and mass spectrometry | |
| Mamone et al. | Analytical and functional approaches to assess the immunogenicity of gluten proteins | |
| US7563864B2 (en) | Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten | |
| KR20170010005A (ko) | 항분비 인자 복합체 분석 | |
| US10466238B2 (en) | Determination of levels of immunogenic gluten peptides in human samples | |
| US20190376982A1 (en) | Detecting Gluten Peptides in Human Fluids | |
| RU2573985C2 (ru) | Применение просоматостатина в диагностике | |
| WO2013098441A1 (es) | Determinación de niveles de péptidos inmunogénicos del gluten en muestras humanas | |
| Jiménez-Saiz et al. | Human IgE binding and in vitro digestion of S-OVA | |
| Mohammed et al. | The Association of Gluten-Free Diet and Liver Function in Iraqi Patientswith Celiac Disease | |
| US20190191748A1 (en) | Method for selecting cereal seeds suitable for consumption by coeliac patients | |
| WO2014031939A1 (en) | Wheat proteomic microarray for biomarker discovery | |
| Arranz et al. | Detection of specific IgA antibodies against a novel deamidated 8-mer gliadin peptide in blood plasma samples from celiac patients | |
| Martínez Abad et al. | Differential immunomodulatory effects of Lactobacillus rhamnosus DR20, Lactobacillus fermentum CECT 5716 and Bifidobacterium animalis subsp. lactis on monocyte-derived dentritic cells |